Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company’s web site at www.santarus.com.
- 16 years ago
QualityStocks
Santarus, Inc. (NASDAQ: SNTS)
Tags Rodman & Renshaw
Related Post
-
QualityStocksNewsBreaks – Nightfood Holdings Inc. (NGTF) Leading Hospitality Tech Revolution with Innovative Solutions
Nightfood Holdings (OTCQB: NGTF) is modernizing the hospitality industry with its AI-driven robotics solutions and innovative…
-
QualityStocksNewsBreaks – SolarBank Corp.’s (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Vision in Action: Building the Grid of Tomorrow
Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a…
-
QualityStocksNewsBreaks – ROTH Conference Marks a Quarter-Century of Community in Dana Point
The 37th Annual ROTH Conference drew thousands of participants from around the globe to Dana…